Clinton Grubbs

Summary

Affiliation: University of Alabama at Birmingham
Country: USA

Publications

  1. ncbi request reprint Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets
    Ruisheng Yao
    Department of Surgery and The Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Carcinogenesis 27:1420-31. 2006
  2. pmc Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene)
    PETER T VEDELL
    Medical College of Wisconsin, Cancer Center, Department of Pharmacology Toxicology, Milwaukee, Wisconsin, USA
    Mol Pharmacol 83:698-708. 2013
  3. ncbi request reprint Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers
    Clinton J Grubbs
    Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294 0019, USA
    Carcinogenesis 27:1232-9. 2006
  4. ncbi request reprint 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers
    Clinton J Grubbs
    Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Cancer Lett 201:17-24. 2003
  5. ncbi request reprint Proteomics analysis of rat brain protein modulations by grape seed extract
    Jessy Deshane
    Department of Pharmacology and Toxicology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama 35294, USA
    J Agric Food Chem 52:7872-83. 2004
  6. ncbi request reprint Chemoprevention by grape seed extract and genistein in carcinogen-induced mammary cancer in rats is diet dependent
    Helen Kim
    Departments of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Nutr 134:3445S-3452S. 2004
  7. ncbi request reprint Prevention of methylnitrosourea-induced mammary cancers by 9-cis-retinoic acid and/or vitamin D3
    Mark B Cope
    University of Alabama at Birmingham, Nutrition Sciences Department, Birmingham, AL 35294, USA
    Oncol Rep 9:533-7. 2002
  8. doi request reprint Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 7:972-9. 2008
  9. ncbi request reprint Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model
    Konstantin Christov
    Department of Surgical Oncology, University of Illinois at Chicago, Chicago, Illinois, USA
    Clin Cancer Res 13:5488-96. 2007
  10. ncbi request reprint Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 5:1073-8. 2006

Research Grants

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets
    Ruisheng Yao
    Department of Surgery and The Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Carcinogenesis 27:1420-31. 2006
    ..Elucidation of gene expression changes in FTI-treated or control rat mammary adenocarcinomas will help in identifying potential pharmacodynamic markers of FTI treatment as well as potential molecular targets of R115777 and other FTIs...
  2. pmc Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene)
    PETER T VEDELL
    Medical College of Wisconsin, Cancer Center, Department of Pharmacology Toxicology, Milwaukee, Wisconsin, USA
    Mol Pharmacol 83:698-708. 2013
    ..Different patterns of gene expression among the agonists provided insight into molecular differences and allowed one to predict certain physiologic consequences of agonist treatment...
  3. ncbi request reprint Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers
    Clinton J Grubbs
    Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294 0019, USA
    Carcinogenesis 27:1232-9. 2006
    ..In summary, a short-term in vivo method has been identified for screening newly synthesized retinoids both for chemopreventive efficacy and for their adverse effect on serum triglycerides...
  4. ncbi request reprint 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers
    Clinton J Grubbs
    Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Cancer Lett 201:17-24. 2003
    ..6; and controls, 6.0. Thus, the combination of the agents resulted in an increased effect in preventing mammary cancers; suggesting that cancer cell proliferation was inhibited by the compounds blocking different pathways...
  5. ncbi request reprint Proteomics analysis of rat brain protein modulations by grape seed extract
    Jessy Deshane
    Department of Pharmacology and Toxicology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama 35294, USA
    J Agric Food Chem 52:7872-83. 2004
    ..This is the first identification and quantitation of specific proteins in mammalian tissues modulated by a dietary supplement, as well as the first to demonstrate links of such proteins with any disease...
  6. ncbi request reprint Chemoprevention by grape seed extract and genistein in carcinogen-induced mammary cancer in rats is diet dependent
    Helen Kim
    Departments of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Nutr 134:3445S-3452S. 2004
    ....
  7. ncbi request reprint Prevention of methylnitrosourea-induced mammary cancers by 9-cis-retinoic acid and/or vitamin D3
    Mark B Cope
    University of Alabama at Birmingham, Nutrition Sciences Department, Birmingham, AL 35294, USA
    Oncol Rep 9:533-7. 2002
    ..Possible interactions between the retinoic acid receptors and vitamin D receptor may be responsible for the observed inhibition of mammary carcinogenesis...
  8. doi request reprint Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 7:972-9. 2008
    ..Finally, combining suboptimal doses of Iressa with suboptimal doses of vorozole (an aromatase inhibitor) or targretin (a retinoid X receptor agonist) yielded greater chemopreventive efficacy than any of these agents given alone...
  9. ncbi request reprint Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model
    Konstantin Christov
    Department of Surgical Oncology, University of Illinois at Chicago, Chicago, Illinois, USA
    Clin Cancer Res 13:5488-96. 2007
    ....
  10. ncbi request reprint Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 5:1073-8. 2006
    ..Thus, R115777 was active in the prevention and therapy of these chemically induced mammary cancers, but was strikingly more effective in cancers with HaRas mutations...
  11. ncbi request reprint Hypermethylation patterns in the Fhit regulatory region are tissue specific
    Gulnur Guler
    Department of Microbiology Immunology, Kimmel Cancer Center, Jefferson Medical College, Philadelphia, Pennsylvania, USA
    Mol Carcinog 43:175-81. 2005
    ..The specific patterns of hypermethylated CpGs in the Fhit regulatory regions thus appear to be tissue-specific...
  12. ncbi request reprint Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer
    Laundette P Jones
    Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20057, USA
    Oncogene 24:3554-62. 2005
    ....
  13. ncbi request reprint Effects of body weight gain reduction resulting from chemopreventive agent treatment on mammary gland morphology
    Cristina Rodriguez-Burford
    Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Nutr Cancer 43:67-75. 2002
    ..It would appear that the observed decrease in mammary cancers observed with moderate reductions in body weight gain might be due to multiple related factors different from those related to 4-HPR treatment...
  14. ncbi request reprint Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Carcinogenesis 26:441-8. 2005
    ..Determination of serum IGF1 levels showed that treatment of rats with highly effective doses of Targretin at 272 mg/kg diet or at 60 or 20 mg/kg body wt/day by gavage caused significantly decreased serum IGF1 levels...
  15. ncbi request reprint Conformationally defined retinoic acid analogues. 5. Large-scale synthesis and mammary cancer chemopreventive activity for (2E,4E,6Z,8E)-8-(3',4'-dihydro-1'(2'H)-naphthalen-1'-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid (9cUAB30)
    Venkatram R Atigadda
    Department of Chemistry, University of Alabama at Birmingham, 901 South 14th Street, Birmingham, AL 35294, USA
    J Med Chem 46:3766-9. 2003
    ..Here, we describe a modified synthesis that yields up to 100 g of 1. We further demonstrate that 1 is very effective in the prevention of N-methyl-N-nitrosourea induced mammary cancers in rats without signs of toxicity...
  16. ncbi request reprint The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial
    Ronald D Alvarez
    Department of Obstetrics and Gynecology, University of Alabama at Birmingham, 35233 7333, USA
    Cancer Epidemiol Biomarkers Prev 12:114-9. 2003
    ..The rate of histological regression in biopsied CIN 2/3 patients is high even over a short time interval, and emphasizes the importance of having a placebo arm and an adequate sample size in cervical dysplasia chemoprevention studies...
  17. ncbi request reprint Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention
    Mark B Cope
    Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Oncol Rep 11:465-9. 2004
    ..In both experiments, the two retinoids in combination produced an additive effect, suggesting that they may inhibit mammary cancers by different mechanisms...
  18. ncbi request reprint Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide
    Yian Wang
    Department of Surgery and The Alvin J Siteman Cancer Center, Campus Box 8109, Washington University School of Medicine, 660 South, Euclid Avenue, St Louis, MO 63110, USA
    Mol Cancer Ther 5:1060-72. 2006
    ..These expression signatures could provide useful pharmacodynamic biomarkers for retinoid treatment and chemoprevention...
  19. ncbi request reprint Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models
    Zhongqiu Zhang
    Department of Surgery and The Alvin J Siteman Cancer Center, Campus Box 8109, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Oncogene 23:3841-50. 2004
    ..Furthermore, ATB exhibited an enhanced inhibitory effect in animals harboring genetic alterations (Kras2, p53, and Ink4a/Arf), which are often seen in human lung adenocarcinomas...
  20. ncbi request reprint Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 6:2022-8. 2007
    ..The bioavailability of these tea polyphenols to different organ sites may contribute to the differing preventive efficacy of Polyphenon E against urinary bladder and mammary cancers...
  21. ncbi request reprint Paradigms for primary prevention of ovarian carcinoma
    Mack N Barnes
    Department of Obstetrics and Gynecology, University of Alabama at Birmingham, USA
    CA Cancer J Clin 52:216-25. 2002
    ..Specifically, in this review, we provide a rationale for chemoprevention of ovarian cancer, a description of promising chemopreventive agents, and an overview of surgical strategies used in the prevention of ovarian cancer...
  22. ncbi request reprint 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Carcinogenesis 26:571-8. 2005
    ..The anti-apoptotic protein survivin was not expressed in normal bladder epithelium, but was variably expressed in cancers. FHIT and survivin expressions were similar in cancers from indomethacin-treated and non-treated mice...
  23. doi request reprint Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
    Int J Cancer 123:2254-9. 2008
    ..In summary, rosiglitazone over a wide dose range enhanced urinary bladder carcinogenesis in the OH-BBN model in rats...
  24. ncbi request reprint Chemoprevention of mammary carcinogenesis in a transgenic mouse model by alpha-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity
    Minglin Li
    Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20057, USA
    Oncogene 22:2568-72. 2003
    ..Alterations in cyclin D1 activity in preneoplastic cells could represent an early biomarker of chemopreventive action and are consistent with a mechanistic role for cyclin D1 in progression of mammary cancer...

Research Grants6

  1. Chemoprevention of Chemically-Induced Bladder Cancers
    Clinton Grubbs; Fiscal Year: 2004
    ..Depending on the results in the FTI treated rats, additional profiles can be assessed in the celecoxib and esculetin treated animals. ..
  2. Prevention of Urinary Bladder Carcinogenesis in Mice
    Clinton Grubbs; Fiscal Year: 2005
    ..Examination of altered RNA levels in cancers and preneoplastic lesions in an animal model will facilitate the development of relevant surrogate biomarkers for cancer chemoprevention studies (one of the stated goals of this RFA). ..